• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Ciprofloxacin therapy in complicated urinary tract infections caused by Pseudomonas aeruginosa and other resistant bacteria.

作者信息

Leigh D A, Emmanuel F X, Petch V J

出版信息

J Antimicrob Chemother. 1986 Nov;18 Suppl D:117-21. doi: 10.1093/jac/18.supplement_d.117.

DOI:10.1093/jac/18.supplement_d.117
PMID:3542943
Abstract

Thirty courses of ciprofloxacin were given to 28 patients with complicated urinary tract infections mainly caused by Pseudomonas aeruginosa. All patients had severe underlying abnormalities and infection usually followed urethral catheterization. The infecting organisms were eradicated from the urine of all patients during therapy and 89% were still clear five to nine days after treatment. At one month follow up the cure rate had fallen to 64%. An increase in resistance to ciprofloxacin was seen in three of the ten failures in infections caused by Ps. aeruginosa. Therapy was well tolerated and few side effects were seen. Ciprofloxacin is a valuable addition to the range of antimicrobial agents available for the treatment of Ps. aeruginosa urinary tract infections particularly in domiciliary practice.

摘要

相似文献

1
Ciprofloxacin therapy in complicated urinary tract infections caused by Pseudomonas aeruginosa and other resistant bacteria.
J Antimicrob Chemother. 1986 Nov;18 Suppl D:117-21. doi: 10.1093/jac/18.supplement_d.117.
2
Complicated urinary tract infections treated with extended-release ciprofloxacin with emphasis on Pseudomonas aeruginosa.用缓释环丙沙星治疗复杂尿路感染,重点关注铜绿假单胞菌。
J Chemother. 2007 Dec;19(6):694-702. doi: 10.1179/joc.2007.19.6.694.
3
The efficacy and safety of ciprofloxacin in the treatment of chronic Pseudomonas aeruginosa urinary tract infection.
J Antimicrob Chemother. 1986 Nov;18 Suppl D:123-7. doi: 10.1093/jac/18.supplement_d.123.
4
Evaluation of the usefulness of a novel injectable cephalosporin, E1040, and ceftazidime for management of complicated urinary tract infections caused by Pseudomonas aeruginosa and Proteus mirabilis by using the rat urolithiasis model.通过大鼠尿路结石模型评估新型注射用头孢菌素E1040和头孢他啶对铜绿假单胞菌和奇异变形杆菌所致复杂性尿路感染的治疗效果。
Antimicrob Agents Chemother. 1992 Jul;36(7):1580-3. doi: 10.1128/AAC.36.7.1580.
5
Efficacy and tolerability of norfloxacin vs. ciprofloxacin in complicated urinary tract infection.
Urology. 1992 Nov;40(5):446-9. doi: 10.1016/0090-4295(92)90461-5.
6
A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial.
J Clin Pharmacol. 1988 Feb;28(2):179-89. doi: 10.1002/j.1552-4604.1988.tb05741.x.
7
Risk factors for urinary tract infections due to ciprofloxacin-resistant Escherichia coli in a tertiary care urology department in Switzerland.瑞士一家三级护理泌尿科部门中,因环丙沙星耐药大肠埃希菌导致的尿路感染的危险因素。
Swiss Med Wkly. 2010 Jul 15;140:w13059. doi: 10.4414/smw.2010.13059. eCollection 2010.
8
Oral ciprofloxacin in the treatment of elderly patients with complicated urinary tract infections due to trimethoprim/sulfamethoxazole-resistant bacteria.
Am J Med. 1987 Apr 27;82(4A):295-300.
9
Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.从土耳其社区获得性尿路感染中分离出的大肠杆菌菌株对环丙沙星耐药的危险因素。
J Antimicrob Chemother. 2005 Nov;56(5):914-8. doi: 10.1093/jac/dki344. Epub 2005 Sep 20.
10
Clinical and laboratory study of tobramycin in the treatment of infections due to gram-negative organisms.妥布霉素治疗革兰氏阴性菌感染的临床及实验室研究
Can Med Assoc J. 1977 Jul 23;117(2):138-43.

引用本文的文献

1
Complicated urinary tract infection in adults.成人复杂性尿路感染。
Can J Infect Dis Med Microbiol. 2005 Nov;16(6):349-60. doi: 10.1155/2005/385768.
2
Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus.环丙沙星诱导铜绿假单胞菌和耐甲氧西林金黄色葡萄球菌对结构不相关抗生素产生低水平耐药性。
Antimicrob Agents Chemother. 1993 Jun;37(6):1289-96. doi: 10.1128/AAC.37.6.1289.
3
Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance.
铜绿假单胞菌和金黄色葡萄球菌中的喹诺酮耐药性。治疗期间的发展及临床意义。
Infection. 1994;22 Suppl 2:S111-21. doi: 10.1007/BF01793575.
4
Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.环丙沙星:抗菌活性、药代动力学特性及治疗用途综述
Drugs. 1988 Apr;35(4):373-447. doi: 10.2165/00003495-198835040-00003.
5
Clinical experience with ciprofloxacin in the treatment of urinary tract infections: a review.
Infection. 1988;16(6):337-44. doi: 10.1007/BF01644543.
6
Increasing rates of in vitro resistance to ciprofloxacin and norfloxacin in isolates from urine specimens.尿液标本分离株对环丙沙星和诺氟沙星的体外耐药率不断上升。
Antimicrob Agents Chemother. 1989 Apr;33(4):595-6. doi: 10.1128/AAC.33.4.595-b.
7
Treatment of genitourinary tract infections with fluoroquinolones: activity in vitro, pharmacokinetics, and clinical efficacy in urinary tract infections and prostatitis.氟喹诺酮类药物治疗泌尿生殖道感染:体外活性、药代动力学及在尿路感染和前列腺炎中的临床疗效
Antimicrob Agents Chemother. 1989 Oct;33(10):1655-61. doi: 10.1128/AAC.33.10.1655.
8
Fluoroquinolone antimicrobial agents.氟喹诺酮类抗菌剂。
Clin Microbiol Rev. 1989 Oct;2(4):378-424. doi: 10.1128/CMR.2.4.378.
9
Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study.环丙沙星与氨基糖苷类药物用于治疗复杂性尿路感染的比较:前瞻性随机临床及药代动力学研究
Antimicrob Agents Chemother. 1991 Sep;35(9):1849-55. doi: 10.1128/AAC.35.9.1849.